Changeflow GovPing Pharma & Drug Safety Blood-brain barrier crossing MLL1-WDR5 inhibito...
Routine Notice Added

Blood-brain barrier crossing MLL1-WDR5 inhibitor compounds

Email

Summary

Blood-brain barrier crossing MLL1-WDR5 inhibitor compounds

Source document (simplified)

← EPO Patent Bulletin

BLOOD-BRAIN BARRIER CROSSING MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR COMPOUNDS AND USES THEREOF

Publication EP4493184A1 Kind: A1 Mar 18, 2026

Applicants

Huyabio International, LLC

Inventors

SHOJAEI, Farbod, FANG, Che, SEMPLE, J. Edward, GILLINGS, Mireille

IPC Classifications

A61K 31/496 20060101AFI20260209BHEP A61K 31/5377 20060101ALI20260209BHEP A61P 25/00 20060101ALI20260209BHEP A61P 35/00 20060101ALI20260209BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.